Genor Biopharma Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2007-12-04
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genorbio.com
Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT03623581
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT03502629
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma
Phase 1
- Conditions
- Interventions
- Biological: Geptanolimab Injection 10mg/kgBiological: Geptanolimab Injection 3mg/kgBiological: Geptanolimab Injection 1mg/kg, q2w*6Biological: Geptanolimab Injection 10mg/kg, , q2w*6Biological: Geptanolimab Injection 3mg/kg, q2w*6Biological: Geptanolimab Injection 1mg/kgBiological: Geptanolimab Injection 280mg, q3wBiological: Geptanolimab Injection 3mg/kg, q2w
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Genor Biopharma Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT03374007
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath